| Dr Nicolette Christine Wise, DO | |
|
1125 Madison St, Jefferson City, MO 65101-5227 | |
| (316) 268-5000 | |
| Not Available |
| Full Name | Dr Nicolette Christine Wise |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 16 Years |
| Location | 1125 Madison St, Jefferson City, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104084888 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 6966 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Capital Region Medical Center | Jefferson city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
| Capital Region Medical Center | 4688573686 | 168 |
News Archive
New research led by Lijun Song, associate professor of sociology at Vanderbilt University, and graduate student Phillip Pettis suggests that knowing people in high and diverse positions may be good or bad for your health. The culprit? Economic inequality.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months.
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
› Verified 9 days ago
| Entity Name | Capital Region Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477980837 PECOS PAC ID: 4688573686 Enrollment ID: O20070323000507 |
News Archive
New research led by Lijun Song, associate professor of sociology at Vanderbilt University, and graduate student Phillip Pettis suggests that knowing people in high and diverse positions may be good or bad for your health. The culprit? Economic inequality.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months.
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
› Verified 9 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
New research led by Lijun Song, associate professor of sociology at Vanderbilt University, and graduate student Phillip Pettis suggests that knowing people in high and diverse positions may be good or bad for your health. The culprit? Economic inequality.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months.
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicolette Christine Wise, DO 1125 Madison St, Jefferson City, MO 65101-5227 Ph: (316) 268-5000 | Dr Nicolette Christine Wise, DO 1125 Madison St, Jefferson City, MO 65101-5227 Ph: (316) 268-5000 |
News Archive
New research led by Lijun Song, associate professor of sociology at Vanderbilt University, and graduate student Phillip Pettis suggests that knowing people in high and diverse positions may be good or bad for your health. The culprit? Economic inequality.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months.
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
› Verified 9 days ago
Scott W. Tanner, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1445 Christy Dr, Jefferson City, MO 65101 Phone: 573-636-3483 Fax: 573-636-5315 | |
Mark R. Frederick, DO Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1445 Christy Dr, Jefferson City, MO 65101 Phone: 573-636-3483 Fax: 573-636-5315 | |
Thomas E Hetherington, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1125 Madison St, Jefferson City, MO 65101 Phone: 573-632-5000 | |
Suzanne M. Pautler, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1445 Christy Dr, Jefferson City, MO 65101 Phone: 573-636-3483 Fax: 573-636-5315 | |
Dr. Deana Michelle Berrey, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-556-5771 | |
Adelia L. Doerhoff, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1445 Christy Dr, Jefferson City, MO 65101 Phone: 573-636-3483 Fax: 573-636-5315 |